CRSP Insider Trading
Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): $313,950.00
Insider Selling (Last 12 Months): $5,714,378.34
CRISPR Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at CRISPR Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
CRISPR Therapeutics Share Price & Price History
Current Price: $36.99
Price Change: ▼ Price Decrease of -1.05 (-2.76%)
As of 03/28/2025 05:00 PM ET
CRISPR Therapeutics Insider Trading History
SEC Filings (Institutional Ownership Changes) for CRISPR Therapeutics (NASDAQ:CRSP)
69.20% of CRISPR Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at CRSP by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
CRISPR Therapeutics Institutional Trading History
Data available starting January 2016
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Read More on CRISPR Therapeutics
Today's Range
Now: $36.99
52 Week Range
Now: $36.99
Volume
1,595,765 shs
Average Volume
1,551,646 shs
Market Capitalization
$3.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.77
Who are the company insiders with the largest holdings of CRISPR Therapeutics?
Who are the major institutional investors of CRISPR Therapeutics?
CRISPR Therapeutics' top institutional shareholders include:
- ARK Investment Management LLC — 10.51%
- Capital International Investors — 10.24%
- T. Rowe Price Investment Management Inc. — 4.47%
- Sumitomo Mitsui Trust Group Inc. — 3.22%
- Nikko Asset Management Americas Inc. — 3.22%
- Vanguard Group Inc. — 2.03%
Learn More about top institutional investors of CRISPR Therapeutics stock.
Which institutional investors are selling CRISPR Therapeutics stock?
During the previous quarter, CRSP stock was sold by these institutional investors:
- Sumitomo Mitsui Trust Group Inc.
- Nikko Asset Management Americas Inc.
- Eagle Health Investments LP
- Millennium Management LLC
- Voloridge Investment Management LLC
- GTS Securities LLC
- Rafferty Asset Management LLC
- Loomis Sayles & Co. L P
In the last year, company insiders that have sold CRISPR Therapeutics company stock include:
- Samarth Kulkarni (CEO)
- James R Kasinger (General Counsel)
- Julianne Bruno (COO)
Learn More investors selling CRISPR Therapeutics stock.
Which institutional investors are buying CRISPR Therapeutics stock?
During the previous quarter, CRSP stock was acquired by institutional investors including:
- ARK Investment Management LLC
- T. Rowe Price Investment Management Inc.
- Capital International Investors
- Baker BROS. Advisors LP
- Norges Bank
- Contrarius Group Holdings Ltd
- IMC Chicago LLC
- Bank of America Corp DE